Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Rating) insider Preethi Sundaram sold 56,786 shares of the business’s stock in a transaction that occurred on Friday, November 11th. The shares were sold at an average price of $16.38, for a total value of $930,154.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Preethi Sundaram also recently made the following trade(s):
- On Thursday, September 15th, Preethi Sundaram sold 18,214 shares of Catalyst Pharmaceuticals stock. The shares were sold at an average price of $14.49, for a total value of $263,920.86.
Catalyst Pharmaceuticals Stock Performance
CPRX opened at $15.23 on Thursday. The business’s fifty day moving average is $13.62 and its two-hundred day moving average is $10.75. The company has a market cap of $1.59 billion, a price-to-earnings ratio of 24.97 and a beta of 1.27. Catalyst Pharmaceuticals, Inc. has a one year low of $5.24 and a one year high of $17.22.
Institutional Trading of Catalyst Pharmaceuticals
Analyst Ratings Changes
CPRX has been the topic of a number of recent research reports. StockNews.com lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 9th. Piper Sandler lifted their price target on Catalyst Pharmaceuticals to $18.00 in a research note on Wednesday. Roth Capital downgraded Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lifted their price target for the company from $10.00 to $15.50 in a research note on Wednesday, August 24th. HC Wainwright lifted their price target on Catalyst Pharmaceuticals from $12.00 to $18.00 and gave the company a “buy” rating in a research note on Thursday, August 11th. Finally, Truist Financial lifted their price target on Catalyst Pharmaceuticals from $12.00 to $17.00 and gave the company a “buy” rating in a research note on Thursday, August 11th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $17.13.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
- Get a free copy of the StockNews.com research report on Catalyst Pharmaceuticals (CPRX)
- International Game Technology is Well Worth the Gamble
- Use The Airbnb Stock Implosion to Your Advantage
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Why Lowe’s Is Up And Home Depot Down
- The TJX Companies Could Break Out To New Highs
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.